Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
tag
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
PFE

Prezzo Pfizer

Closed
PFE
$25,68
-$0,80(-3,02%)

*Data last updated: 2026-05-10 00:33 (UTC+8)

As of 2026-05-10 00:33, Pfizer (PFE) is priced at $25,68, with a total market cap of $146,30B, a P/E ratio of 18,21, and a dividend yield of 6,70%. Today, the stock price fluctuated between $25,60 and $26,19. The current price is 0,31% above the day's low and 1,94% below the day's high, with a trading volume of 32,44M. Over the past 52 weeks, PFE has traded between $23,06 to $28,74, and the current price is -10,64% away from the 52-week high.

PFE Key Stats

Yesterday's Close$26,48
Market Cap$146,30B
Volume32,44M
P/E Ratio18,21
Dividend Yield (TTM)6,70%
Dividend Amount$0,43
Diluted EPS (TTM)1,31
Net Income (FY)$7,77B
Revenue (FY)$62,57B
Earnings Date2026-08-04
EPS Estimate0,68
Revenue Estimate$14,41B
Shares Outstanding5,52B
Beta (1Y)0.305
Ex-Dividend Date2026-05-08
Dividend Payment Date2026-06-12

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
SectorHealthcare
IndustryDrug Manufacturers - General
CEOAlbert Bourla
HeadquartersNew York City,NY,US
Official Websitehttps://www.pfizer.com
Employees (FY)75,00K
Average Revenue (1Y)$834,38K
Net Income per Employee$103,60K

Pfizer (PFE) FAQ

What's the stock price of Pfizer (PFE) today?

x
Pfizer (PFE) is currently trading at $25,68, with a 24h change of -3,02%. The 52-week trading range is $23,06–$28,74.

What are the 52-week high and low prices for Pfizer (PFE)?

x

What is the price-to-earnings (P/E) ratio of Pfizer (PFE)? What does it indicate?

x

What is the market cap of Pfizer (PFE)?

x

What is the most recent quarterly earnings per share (EPS) for Pfizer (PFE)?

x

Should you buy or sell Pfizer (PFE) now?

x

What factors can affect the stock price of Pfizer (PFE)?

x

How to buy Pfizer (PFE) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

PFE
CFD
Fai trading

Hot Posts su Pfizer (PFE)

MrDecoder

MrDecoder

5 ore fa
**Pfizer** (PFE 1.52%) is in a difficult spot right now. It has a number of blockbuster drugs nearing the end of their patent protection, which will likely lead to material revenue declines. It has fallen behind in the GLP-1 weight-loss drug race. And its payout ratio is worryingly high. Here's why you might want to buy it anyway. Wall Street is very downbeat on Pfizer -------------------------------------- As the short list of problems above highlights, Pfizer is not hitting on all cylinders right now. Wall Street knows this, which helps explain why the pharmaceutical company's stock has fallen more than 50% from its 2021 highs. To be fair, that high was partly driven by over-enthusiastic investors, who priced in years of COVID vaccine revenues that didn't materialize. But given the company's long and successful history, investors still seem overly pessimistic about Pfizer's future. Image source: Getty Images. After all, it is one of the world's most respected pharmaceutical companies. And even after losing half its value, it remains an industry giant with a market cap of around $150 billion. Moreover, innovation tends to be lumpy, so patent expirations don't always line up perfectly with new blockbuster drug launches. Given enough time, Pfizer is highly likely to pull out of the business funk it is in. Some silver linings on Pfizer's clouds -------------------------------------- For example, after the company's internal GLP-1 drug was dropped, it quickly pivoted and acquired a company with a more promising drug candidate. Pfizer isn't out of the GLP-1 drug race just yet. Beyond weight-loss drugs, the company is still advancing new migraine and oncology candidates. Given the company's successful history of drug development, it is highly likely that something will eventually click. Expand NYSE: PFE --------- Pfizer Today's Change (-1.52%) $-0.40 Current Price $25.66 ### Key Data Points Market Cap $146B Day's Range $25.60 - $26.20 52wk Range $21.97 - $28.75 Volume 948K Avg Vol 39M Gross Margin 65.16% Dividend Yield 8.37% Meanwhile, management has stated clearly that it intends to maintain the dividend at the current level. Since dividends come out of cash flow and not earnings, it can support the dividend for a little while as it works to get earnings back into growth mode. More aggressive income investors should probably give the company the benefit of the doubt. Pfizer's turnaround offers Income and growth -------------------------------------------- Buying Pfizer sets you up with a 6.5% dividend yield, which is roughly three-quarters of the way to the 10% return investors normally expect from stocks. Meanwhile, the sharp stock price decline positions investors for a rebound as Pfizer's drug pipeline begins to bear fruit. That's a recipe for investment riches, since buying now could mean both a robust income stream and capital appreciation for more intrepid dividend lovers.
0
0
0
0
NoodlesOrTokens

NoodlesOrTokens

12 ore fa
In this article * PFE Follow your favorite stocksCREATE FREE ACCOUNT Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press | Corbis News | Getty Images Pfizer on Tuesday posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as its recently launched and acquired products showed growth. Older top-selling drugs, including its blood thinner Eliquis, also helped drive demand in the quarter and offset the decline in revenue from Pfizer's Covid vaccine and antiviral pill to treat the virus, Paxlovid. Still, the company is slated to face the loss of exclusivity of some older drugs over the next few years, which is expected to weigh on sales. In an interview with CNBC on Tuesday, Pfizer CFO Dave Denton said recently launched and acquired products "will be excelling us through the end of the decade, and that will also partially help us offset the loss during this period." Here's what the company reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:  * **Earnings per share: **75 cents adjusted vs. 72 cents expected * **Revenue: **$14.45 billion vs. $13.79 billion expected The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs. Pfizer is focused on several crucial data releases this year, including late-stage trial results on an experimental targeted drug in lung cancer.  Pfizer reported revenue of $14.45 billion for the first quarter, up 5% from the same period a year ago. Sales increases for key products helped to counteract struggles in its Covid business. The company booked net income of $2.69 billion, or 47 cents per share. That compares with net income of $2.97 billion, or 52 cents per share, during the same period a year ago. Excluding certain items, including restructuring charges and costs associated with intangible assets, Pfizer posted earnings per share of 75 cents for the quarter. Pfizer reaffirmed its 2026 outlook, expecting full-year adjusted profit to come in between $2.80 and $3 per share, and revenue to total $59.5 billion to $62.5 billion. That sales range would be roughly flat or down slightly compared with 2025 revenue of $62.6 billion. Pfizer previously said the lackluster revenue outlook comes in part fromdeclining sales of its Covid vaccine and Paxlovid, which it expects to fall by about $1.5 billion year over year to $5 billion.  The company also pointed to another roughly $1.5 billion year-over-year expected drop in sales due to certain products losing their market exclusivity. Some blockbuster drugs, such as the company's pneumonia vaccine Prevnar, are facing more competition from rivals. The results come a week after Pfizer entered into settlement agreements with three generic drug manufacturers that effectively extend the company's U.S. patent protection for Vyndamax until June 1, 2031. That's a prescription medicine that helps treat a rare, serious heart condition. Those settlement agreements have "the potential to change the growth profile of the company significantly post-2028," Pfizer CEO Albert Bourla said in an earnings call on Tuesday. Newer and older products offset Covid decline ---------------------------------------------- Sales of Pfizer's Covid shot and Paxlovid both came in well under analysts' estimates, according to StreetAccount. The vaccine raked in $232 million in revenue for the quarter, down 59% from the same period a year ago, while Paxlovid sales fell 62% to $186 million. Analysts were expecting sales of $445.9 million and $286.2 million, respectively, for the two products. In an interview on Tuesday, Denton said the company's Covid vaccine franchise "is probably a bit more stable" than Paxlovid, which is more dependent on the number of cases of the virus. "If we have a big season where there's a lot of cases, we'll sell a lot of Paxlovid," Denton said. Meanwhile, Eliquis generated $2.17 billion in sales for the quarter, up 13% from the year-ago period. Analysts expected $1.96 billion in revenue, according to StreetAccount estimates.  Other older drugs and some newer products also beat estimates for the quarter.  Targeted cancer drug Padcev booked $591 million in revenue, up 39% from the same period a year ago and surpassing the $542.3 million that analysts were expecting.  Pfizer's vaccine against respiratory syncytial virus, a more recently launched product, booked $180 million in sales for the first quarter. That's up 37% from the year-earlier period and comes in higher than the $145.1 million that analysts were expecting.  Sales of recently launched and acquired products grew 22% operationally during the quarter, Pfizer said. "That is another set of products that will be excelling us through the end of the decade, that will also partially help us offset the loss during this period," said Denton. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
0
0
0
0
NodeGuardian

NodeGuardian

05-08 08:02
Vanguard Group Inc. increased its stake in Pfizer Inc. by 1.3% during the fourth quarter, acquiring an additional 7.03 million shares to reach a total of 541,346,182 shares valued at approximately $13.48 billion. Pfizer also declared a quarterly dividend of $0.43 per share, representing an annualized yield of 6.4%. Despite beating Q4 EPS and revenue estimates, analysts maintain a "Hold" rating on the stock with an average target price of $28.48.
0
0
0
0